Apogee Therapeutics, Inc.
APGE
Classifica tra le azioni
#2354
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Prezzo delle azioni
$135.07
Ultima sincronizzazione: 2026-09-04
Capitalizzazione di mercato
$8.36B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
144.91%
Paese
US
Scambia Apogee Therapeutics, Inc. (APGE)
Categoria
Healthcare
EPS per Apogee Therapeutics, Inc. (APGE)
EPS al June 2026 TTM: $-4.34
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Apogee Therapeutics, Inc., l’EPS attuale della società (TTM) è $-4.34. Alla fine del 2023, la società aveva un EPS di $-1.66 un aumento rispetto a rispetto a quello del 2022, che era di $-0.79.
Storico EPS per Apogee Therapeutics, Inc. da 2022 a 2026
EPS alla fine di ogni anno
| Anno | EPS | Cambia |
|---|---|---|
| 2026 (TTM) | $-4.34 | 31.52% |
| 2024 | $-3.30 | 98.80% |
| 2023 | $-1.66 | 110.13% |
| 2022 | $-0.79 | 0.00% |
EPS per aziende simili o concorrenti
| Azienda | EPS | Differenza di EPS | Il paese |
|---|---|---|---|
| $17.32 | -499.08% |
US
|
|
| $-7.98 | 83.87% |
US
|
|
| $-5.29 | 21.89% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -739.17% |
NL
|
